title: Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?
abstract: Responses to drug therapy vary from benefit to no effect to adverse effects which can be serious or occasionally fatal. Increasing evidence supports the idea that genetic variants can play a major role in this spectrum of responses. Well-studied examples in cardiovascular therapeutics include predictors of steady-state warfarin dosage, predictors of reduced efficacy among patients receiving clopidogrel for drug eluting stents, and predictors of some serious adverse drug effects. This review summarizes contemporary approaches to identifying and validating genetic predictors of variability in response to drug treatment. Approaches to incorporating this new knowledge into clinical care, and the barriers to this concept, are addressed.
authors.affiliation: Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA. dan.roden@vanderbilt.edu
authors.forename: Dan M
authors.initials: DM
authors.lastname: Roden
mesh_terms: D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000235:genetics*; D002319:Cardiovascular System / Q000187:drug effects*; D006801:Humans; D010597:Pharmacogenetics / Q000639:trends*
chemical_list: D002317:Cardiovascular Agents